Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
GSK Investigational Site, Stockholm, Sweden
M D Anderson Cancer Center, Houston, Texas, United States
CRLC Caen, Caen, France
CHU Limoges, Limoges, France
CHU Besançon, Besançon, France
Caitlin Guzowski, Atlanta, Georgia, United States
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
TCRCure Biopharma Ltd., Chongqing, China
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Hospital Universitario Reina Sofia, Cordoba, Spain
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.